Serotonin News and Research

Latest Serotonin News and Research

Link between eating nuts and higher levels of serotonin in MetS patients

For the first time, scientists report a link between eating nuts and higher levels of serotonin in the bodies of patients with metabolic syndrome (MetS), who are at high risk for heart disease.

3 Nov 2011

J&JPRD submits NUCYNTA ER sNDA to FDA for DPN associated neuropathic pain

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. announced today that it has submitted a supplemental New Drug Application to the U.S. Food and Drug Administration for NUCYNTA ER (tapentadol) extended-release tablets, an oral analgesic, for the management of neuropathic pain associated with diabetic peripheral neuropathy in adults.

31 Oct 2011

Forest Laboratories second quarter net sales increase 9.0% to $1,130.3 million

Forest Laboratories, Inc., an international pharmaceutical manufacturer and marketer, announced that reported earnings per share equaled $0.91 in the second quarter of fiscal 2012. Reported earnings per share in the second quarter of fiscal 2011 were $1.00.

18 Oct 2011

HHWC medical doctors provide insight into depression

A staggering 230 million antidepressant prescriptions are filled each year. Yet the face of depression does not always fit the mold: a successful career, loving spouse, wonderful children, seemingly good health and finances. From the outside life appears perfect, so why are Americans depressed?

15 Oct 2011

AiC: Health Research receives U.S. Army grant for neuroimaging studies of human performance

The Arlington Innovation Center: Health Research (AiC: Health Research), of Virginia Tech's National Capital Region, has been awarded a $1.5 million cooperative research and development agreement from the U.S. Army for neuroimaging studies of human performance.

14 Oct 2011

FDA approves NDA for Edgemont's Fluoxetine 60 mg tablet

Edgemont Pharmaceuticals, LLC, a neuroscience focused company, today announced that the U.S. Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for Fluoxetine Tablets 60 mg.

12 Oct 2011

PE, CT appear to reduce PTSD symptoms in patients with recent traumatic event

Prolonged exposure therapy, cognitive therapy, and delayed prolonged exposure therapy, appear to reduce posttraumatic stress disorder symptoms in patients who have experienced a recent traumatic event, according to a report published Online First by Archives of General Psychiatry, one of the JAMA/Archives journals.

4 Oct 2011

Novel binding assay can simplify search for potential SERT inhibitors

Many psychiatric conditions are caused by aberrant metabolism of the neurotransmitter serotonin. Researchers in the Department of Pharmacy at LMU have now developed a new screening method, which will facilitate the search for new drugs that modulate the biological activity of serotonin.

1 Oct 2011

Study links pain severity with depression

A new study in The Journal of Pain, published by the American Pain Society, www.ampainsoc.org, shows that changes in pain severity can predict subsequent depression severity and, likewise, a worsening change in depression is an equally strong predictor of subsequent pain severity.

29 Sep 2011

Arena, Eisai announce new data from lorcaserin Phase 3 clinical trial program

Arena Pharmaceuticals, Inc. and Eisai Inc. announced today that new data analyses from the lorcaserin Phase 3 clinical trial program will be presented in poster sessions at Obesity 2011, the 29th Annual Scientific Meeting of The Obesity Society in Orlando, Florida.

27 Sep 2011

Anti-obesity drug Contrave may get another chance to prove itself

With rise obesity around the world there should have been a number of drugs to combat it. The reality is different. There are no safe and effective drugs in the market at present.

22 Sep 2011

Jefferson experts review most commonly used CAM practices for mood disorders

Mood disorders are among the most prevalent mental health issues today. While medication is available, more and more people are turning to complementary and alternative medicine (CAM), including herbal remedies, acupuncture, and meditation to help manage their mood disorders.

22 Sep 2011

Combination of SRIs and cognitive behavior therapy reduces pediatric OCD symptoms

Children and teens with obsessive-compulsive disorder (OCD) who were receiving some benefit from treatment with medication had a significantly greater reduction in OCD symptoms with the addition of cognitive behavior therapy, according to a study in the September 21 issue of JAMA.

21 Sep 2011

Researchers reveal crystal structure of dynamin protein

The crystal structure of the dynamin protein - one of the molecular machines that makes cells work - has been revealed, bringing insights into a class of molecules with a wide influence on health and disease.

19 Sep 2011

U of C researchers create new model of obsessive-compulsive disorder

A new model of obsessive-compulsive disorder (OCD) that mirrors both symptoms of the disease and the timing of its treatment in humans has been created by University of Chicago researchers, according to a new study.

16 Sep 2011

New insight into why some individuals may be more aggressive than others

Fluctuations of serotonin levels in the brain, which often occur when someone hasn't eaten or is stressed, affects brain regions that enable people to regulate anger, new research from the University of Cambridge has shown.

16 Sep 2011

Gene variants that help regulate serotonin may serve as predictor of risk for PSTD symptoms

Data in a study published in the Archives of General Psychiatry suggest that certain variants of a gene that helps regulate serotonin, may serve as a useful predictor of risk for symptoms related to posttraumatic stress disorder (PTSD) following a trauma.

6 Sep 2011

UTHealth to study BMS-820836 in Phase II trial for major depressive disorder

A new medication to treat major depressive disorder in patients who have not responded to other antidepressants is being studied in a Phase II clinical trial by researchers at The University of Texas Health Science Center at Houston.

2 Sep 2011

Health Canada accepts Sunovion Pharmaceuticals Canada's lurasidone NDS for review

Sunovion Pharmaceuticals Canada Inc., formerly Sepracor Pharmaceuticals, Inc., today announced that the New Drug Submission (NDS) for Lurasidone HCl, for the treatment of adult patients with schizophrenia has been accepted for review by Health Canada. The NDS was submitted to Health Canada in June 2011 and will receive a standard review.

24 Aug 2011

Daily exercise can work as well as second antidepressant drug

Exercise can be as effective as a second medication for as many as half of depressed patients whose condition have not been cured by a single antidepressant medication.

24 Aug 2011